Index RUT
P/E -
EPS (ttm) -0.91
Insider Own 5.89%
Shs Outstand 99.01M
Perf Week -11.27%
Market Cap 1.35B
Forward P/E -
EPS next Y -1.02
Insider Trans -16.33%
Shs Float 93.71M
Perf Month -7.38%
Income -74.10M
PEG -
EPS next Q -0.22
Inst Own 35.70%
Short Float / Ratio 13.78% / 5.74
Perf Quarter -38.94%
Sales -
P/S -
EPS this Y -25.80%
Inst Trans -0.31%
Short Interest 12.91M
Perf Half Y 38.94%
Book/sh 3.90
P/B 3.41
EPS next Y -13.30%
ROA -33.40%
Target Price 33.80
Perf Year 333.55%
Cash/sh 3.87
P/C 3.44
EPS next 5Y 40.00%
ROE -36.30%
52W Range 2.53 - 25.72
Perf YTD 41.60%
Dividend -
P/FCF -
EPS past 5Y -2.50%
ROI -
52W High -48.25%
Beta 0.53
Dividend % -
Quick Ratio 29.60
Sales past 5Y -
Gross Margin -
52W Low 425.15%
ATR 0.74
Employees 22
Current Ratio 29.60
Sales Q/Q -
Oper. Margin -
RSI (14) 37.39
Volatility 5.42% 4.89%
Optionable Yes
Debt/Eq 0.00
EPS Q/Q 14.40%
Profit Margin -
Rel Volume 0.49
Prev Close 13.49
Shortable Yes
LT Debt/Eq 0.00
Earnings Jul 26 AMC
Payout -
Avg Volume 2.25M
Price 13.31
Recom 1.50
SMA20 -7.47%
SMA50 -8.03%
SMA200 -7.37%
Volume 1,099,159
Change -1.33%
Date
Action
Analyst
Rating Change
Price Target Change
May-31-23 Resumed
ROTH MKM
Buy
$32
Mar-28-23 Reiterated
Maxim Group
Buy
$15 → $25
Mar-17-23 Initiated
Stifel
Buy
$22
Jul-29-21 Resumed
BTIG Research
Buy
$20
May-25-21 Downgrade
Raymond James
Strong Buy → Outperform
$27 → $12
Jun-05-20 Initiated
BMO Capital Markets
Outperform
$14
May-05-20 Initiated
Chardan Capital Markets
Buy
$15
May-01-20 Initiated
BTIG Research
Buy
$9
Jul-16-19 Initiated
Oppenheimer
Outperform
$12
Jun-25-19 Initiated
Stifel
Buy
Mar-29-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
$10 → $21
Mar-14-19 Reiterated
Maxim Group
Buy
$28 → $20
Feb-22-19 Initiated
SVB Leerink
Mkt Perform
Dec-12-18 Initiated
B. Riley FBR
Buy
$16
Nov-19-18 Upgrade
Raymond James
Outperform → Strong Buy
Sep-18-18 Reiterated
Raymond James
Outperform
$15 → $43
Sep-18-18 Reiterated
Maxim Group
Buy
$14 → $28
Sep-18-18 Reiterated
H.C. Wainwright
Buy
$15 → $28
Jul-20-18 Initiated
SunTrust
Buy
$14
Jun-28-18 Initiated
Raymond James
Outperform
Show Previous Ratings
Sep-07-23 04:05PM
Sep-06-23 07:03AM
Aug-28-23 10:22AM
Aug-17-23 09:31AM
Aug-16-23 07:07PM
11:45AM
Loading…
Aug-09-23 11:45AM
Aug-08-23 11:45AM
Aug-02-23 11:15AM
Jul-29-23 11:39AM
Jul-27-23 09:51AM
(Thomson Reuters StreetEvents)
Jul-26-23 04:05PM
Jul-22-23 06:14AM
Jul-19-23 04:05PM
Jul-12-23 10:05AM
Jul-10-23 09:32AM
09:29AM
Loading…
09:29AM
Jul-07-23 06:32PM
08:00AM
(The Wall Street Journal)
Jul-05-23 08:14PM
Jun-29-23 02:00PM
08:30AM
Jun-27-23 01:53PM
Jun-26-23 11:39PM
Jun-22-23 06:40AM
Jun-20-23 10:15AM
05:50AM
05:25AM
Jun-17-23 09:06AM
Jun-13-23 11:15AM
Jun-12-23 10:15AM
11:14AM
Loading…
Jun-08-23 11:14AM
10:07AM
Jun-07-23 07:13AM
May-31-23 02:49PM
May-30-23 05:38AM
May-26-23 06:19AM
May-24-23 11:59AM
May-22-23 12:02PM
06:40AM
May-21-23 03:28PM
May-19-23 03:27PM
May-18-23 02:52PM
12:12PM
May-17-23 01:59PM
May-16-23 04:12PM
(Investor's Business Daily) +12.07%
03:52PM
11:29AM
(Investor's Business Daily)
09:32AM
(Investor's Business Daily)
07:31AM
07:00AM
May-11-23 08:39AM
May-09-23 03:40PM
May-01-23 04:28PM
Apr-27-23 02:56PM
06:31AM
(Thomson Reuters StreetEvents)
Apr-26-23 04:05PM
Apr-25-23 08:45AM
07:12AM
Apr-20-23 04:05PM
Apr-19-23 02:42PM
Apr-11-23 04:05PM
Apr-07-23 06:40PM
Apr-03-23 05:06PM
Apr-01-23 01:43PM
Mar-30-23 02:06PM
01:48AM
Mar-29-23 04:10PM
(Investor's Business Daily)
04:01PM
12:51PM
(Investor's Business Daily)
11:24AM
07:45AM
05:54AM
Mar-28-23 04:18PM
(Investor's Business Daily) +69.30%
04:18PM
(Investor's Business Daily)
12:32PM
(Investor's Business Daily)
07:03AM
07:00AM
06:33AM
Mar-27-23 05:47AM
Mar-15-23 03:28PM
Mar-07-23 04:05PM
Feb-23-23 10:30AM
Feb-11-23 07:05AM
Feb-08-23 04:05PM
Feb-07-23 04:05PM
Feb-01-23 04:05PM
Jan-12-23 06:06AM
Jan-09-23 07:05AM
Dec-28-22 09:29PM
Dec-19-22 08:42AM
Dec-09-22 12:00PM
Nov-22-22 08:30AM
Nov-16-22 06:01AM
Nov-08-22 04:05PM
Oct-26-22 04:05PM
Oct-19-22 04:05PM
Oct-06-22 03:09PM
Sep-15-22 11:38AM
Sep-06-22 04:05PM
Aug-05-22 06:51AM
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rowland Charles A Jr Director May 16 Option Exercise 1.08 40,000 43,200 70,000 May 18 06:31 PM MACARTNEY LAWSON Director May 16 Option Exercise 1.19 16,000 19,040 63,965 May 18 06:30 PM Rowland Charles A Jr Director May 16 Sale 25.00 40,000 1,000,000 30,000 May 18 06:31 PM MACARTNEY LAWSON Director May 16 Sale 24.00 16,000 384,000 47,965 May 18 06:30 PM Lian Brian President & CEO May 01 Sale 22.45 45,000 1,010,250 2,197,963 May 01 07:03 PM MACARTNEY LAWSON Director Apr 24 Option Exercise 3.33 16,000 53,280 63,965 Apr 24 07:31 PM MACARTNEY LAWSON Director Apr 24 Sale 22.00 16,000 352,061 47,965 Apr 24 07:31 PM Lian Brian President & CEO Apr 19 Sale 21.45 35,000 750,750 2,242,963 Apr 21 07:29 PM Lian Brian President & CEO Apr 17 Option Exercise 2.15 125,000 268,750 2,432,963 Apr 18 07:09 PM MACARTNEY LAWSON Director Apr 17 Option Exercise 8.00 20,786 166,288 68,751 Apr 18 07:10 PM Mancini Marianna Chief Operating Officer Apr 17 Option Exercise 13.07 12,500 163,375 300,263 Apr 18 07:08 PM ZANTE GREG Chief Financial Officer Apr 17 Option Exercise 13.07 7,500 98,025 156,779 Apr 18 07:07 PM Lian Brian President & CEO Apr 17 Sale 20.45 155,000 3,169,766 2,277,963 Apr 18 07:09 PM MACARTNEY LAWSON Director Apr 17 Sale 20.00 20,786 415,720 47,965 Apr 18 07:10 PM Mancini Marianna Chief Operating Officer Apr 17 Sale 20.00 12,500 250,000 287,763 Apr 18 07:08 PM ZANTE GREG Chief Financial Officer Apr 17 Sale 20.00 7,500 150,000 149,279 Apr 18 07:07 PM Lian Brian President & CEO Apr 13 Option Exercise 1.88 54,336 102,152 2,387,299 Apr 13 05:14 PM Lian Brian President & CEO Apr 13 Sale 18.45 79,336 1,463,749 2,307,963 Apr 13 05:14 PM ZANTE GREG Chief Financial Officer Apr 12 Option Exercise 5.99 41,544 249,026 190,823 Apr 13 05:13 PM ZANTE GREG Chief Financial Officer Apr 12 Sale 18.00 41,544 747,792 149,279 Apr 13 05:13 PM ZANTE GREG Chief Financial Officer Apr 11 Option Exercise 5.25 56,295 295,778 205,574 Apr 13 05:13 PM ZANTE GREG Chief Financial Officer Apr 11 Sale 18.00 56,295 1,013,518 149,279 Apr 13 05:13 PM ZANTE GREG Chief Financial Officer Apr 03 Option Exercise 7.77 30,911 240,178 178,689 Apr 03 07:24 PM ZANTE GREG Chief Financial Officer Apr 03 Sale 18.00 30,911 556,398 147,778 Apr 03 07:24 PM Lian Brian President & CEO Apr 03 Sale 17.85 22,000 392,700 2,232,963 Apr 03 07:26 PM Lian Brian President & CEO Mar 31 Option Exercise 9.49 67,970 645,035 2,322,933 Apr 03 07:26 PM Lian Brian President & CEO Mar 31 Sale 17.45 67,970 1,186,076 2,254,963 Apr 03 07:26 PM ZANTE GREG Chief Financial Officer Mar 30 Option Exercise 7.29 93,750 683,482 278,807 Apr 03 07:24 PM Lian Brian President & CEO Mar 30 Option Exercise 2.42 135,382 327,838 2,408,345 Apr 03 07:26 PM Mancini Marianna Chief Operating Officer Mar 30 Option Exercise 8.12 36,100 293,122 297,995 Apr 03 07:22 PM Lian Brian President & CEO Mar 30 Sale 17.16 153,382 2,632,516 2,254,963 Apr 03 07:26 PM ZANTE GREG Chief Financial Officer Mar 30 Sale 17.00 131,029 2,227,821 147,778 Apr 03 07:24 PM Mancini Marianna Chief Operating Officer Mar 29 Option Exercise 9.13 15,000 136,950 303,137 Mar 30 09:04 PM Mancini Marianna Chief Operating Officer Mar 29 Sale 16.00 41,242 659,872 261,895 Mar 30 09:04 PM Mancini Marianna Chief Operating Officer Mar 28 Option Exercise 2.37 167,427 397,193 484,700 Mar 30 09:04 PM Mancini Marianna Chief Operating Officer Mar 28 Sale 15.00 196,563 2,948,445 288,137 Mar 30 09:04 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite